Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...

Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments ...

Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

AstraZeneca (Nasdaq: AZN) Roche (OTCQX: RHHBY) September 17, 2024 - Investorideas , a go-to investing platform, releases the first of a two-part series looking at news and developments for the ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from two clinical trials of nadunolimab combination therapy in 55 patients with primarily lung cancer and head and neck cancer.

1 “It seems the outcome with this combination of pembrolizumab and lenvatinib, surpasses the activity of any of these agents as monotherapy,” Jordi Remon, MD, PhD, Department of Cancer Medicine, ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will highlight new data from across its approved and investigational cancer therapies during the 2024 European Society ...

Phase 1c study of PRTH-101 alone or in combination with KEYTRUDA® in patients with advanced or metastatic solid tumors will inform optimal design of the Phase ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma.